BOLT — Bolt Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1641281 ·
Last close
$3.65
Market Cap
$7.03M
52W High
$7.20
52W Low
$3.10
ADV30
31,265
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,000 | — | -7,566,000 | -7,720,000 | 40,344,000 | 12,860,000 | 27,704,000 |
| Mar 2026 | 26,000 | — | -7,601,000 | -7,244,000 | 48,027,000 | 11,609,000 | 28,205,000 |
| Dec 2025 | 2,500,000 | — | -5,605,000 | -6,631,000 | 56,748,000 | 11,703,000 | 30,243,000 |
| Sep 2025 | 2,169,000 | — | -7,703,000 | -7,144,000 | 65,053,000 | 17,753,000 | 32,952,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,508,000
Investing CF
$37,674,000
Financing CF
$25,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.33
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-468,023,000
Inventory
—
Receivables
$973,000
ST Investments
$11,283,000
EBIT TTM
$-30,119,000
Pretax Income TTM
$-29,580,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,700,000
EBITDA
$-27,556,000
Free Cash Flow
$-18,791,876
Enterprise Value
$11,635,063
Total Cash
$17,598,000
Total Debt
$21,624,000
Shares Out
1,926,345
Trailing EPS
$-16.51
Book Value
$6.56
ROE
-111.6%
ROA
-30.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,695,000 | -34,633,000 | -33,376,000 | 56,748,000 | 30,243,000 | 26,505,000 | -39,850,000 |
| Dec 2024 | 7,690,000 | -68,236,000 | -63,118,000 | 99,632,000 | 42,434,000 | 57,198,000 | -61,289,000 |
| Dec 2023 | 7,876,000 | -76,196,000 | -69,197,000 | 159,784,000 | 47,043,000 | 112,741,000 | -69,525,000 |
| Dec 2022 | 5,729,000 | -90,321,000 | -88,098,000 | 227,807,000 | 56,301,000 | 171,506,000 | -76,504,000 |
TTM Snapshot
Revenues TTM
$6,499,000
NetIncome TTM
$-29,580,000
OpCashFlow TTM
—
Assets (Latest)
$48,027,000
Forward EPS
$-20.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | $7.03M | $0.56 | — |
| LGVN | Longeveron Inc. | $7.21M | $2.37 | — |
| ENVB | Enveric Biosciences, Inc. | $6.80M | $1.52 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $6.79M | $3.58 | — |
| INM | InMed Pharmaceuticals Inc. | $7.31M | $1.33 | — |
News headlines (Yahoo Finance, 1h cache)
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates
2026-08-11 21:45 · Yahoo
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:40 · Yahoo
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
2026-06-01 17:00 · Yahoo
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project
2026-06-12 11:00 · Yahoo
Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary
2026-04-09 07:00 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
2026-03-12 21:45 · Yahoo
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-03-12 20:05 · Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
2025-11-12 22:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.